A First-in-Human Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Novel Anti-Interleukin 1 Biologic Agent, Rph-104, in Healthy Subjects

Basit Öğe Kaydı
dc.contributor.authorGul, Ahmet
dc.contributor.authorUlker, Sibel
dc.contributor.authorSenturk, Recep Selim
dc.contributor.authorTurk, Ugur Onsel
dc.contributor.authorGurgun, Cemil
dc.contributor.authorLavrovsky, Yan
dc.contributor.authorSamsonov, Mikhail
dc.contributor.authorOzen, Sebnem
dc.contributor.authorAltinel, Serdar
dc.date.accessioned2019-10-27T11:05:10Z
dc.date.available2019-10-27T11:05:10Z
dc.date.issued2017
dc.departmentEge Üniversitesien_US
dc.identifier.issn2326-5191
dc.identifier.issn2326-5205
dc.identifier.urihttps://hdl.handle.net/11454/31618
dc.identifier.volume69en_US
dc.identifier.wosWOS:000411824102080en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofArthritis & Rheumatologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleA First-in-Human Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Novel Anti-Interleukin 1 Biologic Agent, Rph-104, in Healthy Subjectsen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu